Return

Histologic and combined histologic–endoscopic outcomes with mirikizumab in Crohn’s disease: VIVID-1 trial results

2026-06-17

Vipul Jairath

Fernando Magro

Marijana Protic *

Gert De Hertogh

Noam Harpaz

Tadakazu Hisamatsu

Geert D’Haens

Rish Pai

Guanglei Yu

Nathan Morris

Wen Tao Luo

Emily Hon

Rodrigo Escobar

Luc Biedermann

Walter Reinisch

for the VIVID Study Group

DOI：10.1093/ecco-jcc/jjag077

Original

Original request for help

Save

Abstract

En 中文

Evaluation of microscopic inflammation is an emerging therapeutic target of Crohn’s disease. The completed VIVID-1 trial evaluated histologic and combined histologic–endoscopic outcomes for mirikizumab relative to placebo and ustekinumab in moderately-to-severely active Crohn’s disease.